178312-48-6

Basic information

• Product Name: Cyclohexanemethanol, 4,4-difluoro- (9CI)
• Synonyms: Cyclohexanemethanol, 4,4-difluoro- (9CI);4,4-Difluoro-cyclohexaneMethanol;CyclohexaneMethanol, 4,4-difluoro-;(4,4-Difluorocyclohexyl)Methanol;4,4-Difluorocyclohexane-1-methanol
• CAS NO: 178312-48-6
• Molecular Formula: C₇H₁₂F₂O
• Molecular Weight: 150.1663864
• Product Categories: HALIDE
• Mol File: 178312-48-6.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 181.4 °C at 760 mmHg
• Flash Point: 101℃
• Appearance: /
• Density: 1.154 g/mL at 25 °C
• Refractive Index: n20/D1.431
• Storage Temp.: 2-8°C
• PKA: 15.05±0.10(Predicted)
• CAS DataBase Reference: Cyclohexanemethanol, 4,4-difluoro- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclohexanemethanol, 4,4-difluoro- (9CI)(178312-48-6)
• EPA Substance Registry System: Cyclohexanemethanol, 4,4-difluoro- (9CI)(178312-48-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 178312-48-6(Hazardous Substances Data)

Usage

Uses

(4,4-Difluorocyclohexyl)methanol acts as a reagent in the preparation and anti-HIV activity of fluorinated betulinic acid derivatives.

Upstream product

• 122665-97-8 4,4-difluorocyclohexanecarboxylic acid 
• 3618-04-0 4-hydroxycyclohexyl carboxylic acid ethyl ester 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 121629-14-9 methyl 4,4-difluorocyclohexane-1-carboxylate 
• 178312-47-5 ethyl 4,4-difluorocyclohexane-1-carboxylate 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 265108-36-9 4,4-difluorocyclohexane carboxyaldehyde 
• 858121-94-5 4-(bromomethyl)-1,1-difluorocyclohexane 

Relevant articles and documents

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

HYDROXYL PURINE COMPOUNDS AND USE THEREOF

Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNFα inhibitors, in particular, the compounds as shown in formula (I), or tautomers thereof or pharmaceutically acceptable salts thereof.

OXABOROLE ESTERS AND USES THEREOF

The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.